Professional Documents
Culture Documents
Danny Suwandi Department of Pharmacology & Therapeutics Faculty of Medicine Hasanuddin University
Coronary heart disease (12.2%) Stroke and other cerebrovascular diseases (9.7%) Lower respiratory infections (7.1%) Chronic obstructive pulmonary disease (5.1%) Diarrheal diseases (3.7%) HIV/AIDS (3.5%) Tuberculosis (2.5%) Trachea, bronchus, lung cancers (2.3%) Road traffic accidents (2.2%) Prematurity and low birth weight (2%)
Perkembangan terapi antibiotika dalam 7 dasawarsa terakhir ini sangat pesat, tetapi angka morbiditas/mortalitas penyakit infeksi tetap tinggi Masalah :
1. Pemilihan antibiotika makin beragam 2. Penggunaan antibiotika cenderung tidak rasional Resistensi 3. Biaya kesehatan meningkat
Strategi :
Pemahaman mengenai : 1. Klasifikasi anti-infeksi/antibiotika 2. Dasar-dasar penggunaan 3. Akibat serta penanggulangannya
Conventional Antibiotics
Penicillin Cephalosporin Carbapenems Quinolones Aminoglycosides Macrolides Tetracycline Nitrofurantoin, Metronidazole, clindamycin, vancomycin, teicoplanin, cotrimoxazole, fusidic acid, etc. Isoniazid, pyrazinamide, ethambutol, rifampicin, cycloserin, etc.
Langkah-langkah
Penegakan diagnosa infeksi Kemungkinan kuman penyebabnya Apakah antibiotik benar-benar diperlukan Alternatif Jika diperlukan antibiotika : Spektrum antikuman Pola sensitifitas Sifat farmakokinetik Ada tidaknya kontra indikasi Ada tidaknya interaksi yang merugikan Penentuan dosis, cara pemberian, lama pemberian, evaluasi dan efek samping Keadaan fisik pasien seperti : adanya kelainan ginjal, fungsi hati, usia, berat badan dan sebagainya Harga
1. 2.
Is an antibiotic indicated? Have appropriate specimens been obtained, examined and cultured? 3. What organism are most likely? 4. If several antibiotics are available, which is the best? 5. Is an antibiotic combination appropriate? 6. What are the important host factors? 7. What is the best route of administration? 8. What is the appropriate dose? 9. Will initial therapy require modification after culture date are returned? 10. What is the optimal duration of treatment, and is development of resistance during prolonged therapy likely to occur?
All of the above action will exhibit bactericidal effects, except the action on protein synthesis and folic acid antagonist resulting bacteriostatic effects For some indications combination therapy is indicated. However the bacteriostatic or bactericidal agents should not be mixed (Chris J.V. Boxtel, Drug Benefits and Risks, 2001)
Select a regiment that maximize the rate and extent of bacterial killing Rationale : Suboptimal therapy maybe life threatening in the treatment of severe infections Slow bacterial killing will likely give chance for the responsible pathogen to develop resistance.
The concept of Pharmacokinetic/Pharmacodynamics (PK/PD) has been increasingly applied to optimize the clinical use of antimicrobial agents and delay the growth of resistant pathogens to promote rational use of drug
Penentuan dosis yang lebih benar dan tepat Peramalan efikasi kliniknya Peramalan kemungkinan terjadinya resistensi kuman selama pengobatan Berguna bagi penentuan formulasi pengembangan antibiotika yang baru
concentration
Relationship between the pharmacokinetic profile of an antibiotic and the minimum inhibitory concentration against a hypothetical target organism
Minimum inhibitory concentration (MIC)
Time above minimum inhibitory concentration Peak (Cmax) Area under the curve > minimum inhibitory concentration (AUC)
A
B C D
A B
time
Adapted from:
Cmax
MIC
time
MIC
time
Antibiotics : The more you use it, the faster you lose it
Antibiotic resistance are increasing and actually around the world Development of bacterial resistance to antibiotics is much faster than research and development of new antibiotics (Robert A. Weinstein, The Epidemiology of Antibiotic Resistance, June 2007) But doctors can improve their prescribing practices and thats a big effort in hospitals
Outcomes Measure
Relative Risk of Worse Outcomes for Infections with Resistant Compared with Susceptible Bacteria
1.0 1.7 1.0 1.7 1.3 5.0
Adapted from: Centers for Disease Control and Prevention Bulletin. Nov 17, 2010)
Extended spectrum beta-lactamases producing Enterobacteriaceae e.g. Escherichia coli, Klebsiella pneumoniae
Multidrug resistant pseudomonas aeruginosa Multidrug resistant acinetobacter baumannii Pan-resistant Pseudomonas aeruginosa/Acinetobacter baumannii
The 10x20 Initiative : Pursuing global commitments to develop 10 new antibacterial drugs by 2020
Adapted from : Clinical Infection Diseases 2010:50:1081-1083
Keuntungan :
Memperpendek masa rawat Mengurangi kejadian nosokomial melalui jarum infus Mengurangi komplikasi thromboflebitis Menurunkan biaya pengobatan Switch Therapy Obat IV dan oral berlainan namun potensi antibakterinya sama Sequential Therapy Obat IV dan oral adalah sama dan obat oral diserap dengan baik mis: ofloksasin Stepdown Therapy Obat IV dialihkan ke oral yang potensinya lebih lemah. Mis : ceftriaxone IV ke cefuroxime aksetil oral
Perbaikan klinis atau parameter infeksi lain setelah 2-3 hari Tidak adanya indikasi lanjutan diberi antibiotika IV Tidak ada gangguan pada saluran cerna Bebas demam lebih kurang dua hari Adanya perubahan leukosit, hitung jenis dan protein fase akut ke arah normal
Meningitis Intracranial abscess Infective endocarditis Mediastinitis Severe infections during chemotherapy-related neutropenia Inadequately drained abscess and empyema Severe soft tissue infections S. aureus or P. aeruginosa bacteremia
Involves
Prescribing antimicrobial therapy only when it is beneficial to the patient Targeting therapy to the desired pathogens Using the appropriate drug, dose and duration
Objectives
Control the emergence and spread of antibiotic resistance Optimize selection and use of antibiotics Cost containment
Multidisciplinary, programmatic, prospective, interventional approach to optimizing the use of antimicrobial agents The multidisciplinary team typically includes
Clinical microbiologists Infectious diseases specialists Clinical pharmacists Infection control practitioners
MRSA : vancomycin, teicoplanin, linezolid and daptomycin ESBL : Carbapenems, piperacillintazobactum, cefaperozone-sulbactum, amoxycillin-clavulinate Enterococcus : linezolid, teicoplanin, vancomycin Acinetobacter : colistin in combinations with rifampin and imipenem, rifampin and ampicilin-sulbactam or colistin and rifampin only VRE : Linezolid, daptomycin, high dose ampicillin with aminoglycoside
Adapted from: A.Bhagwati, Guidelines for antibiotic usage in common situations, Dec.2010)
Resistensi terhadap antibiotika tetap berkembang pesat Penggunaan antibiotika harus sesuai indikasi dengan segala aspeknya Upaya penghematan biaya penderita di RS (terapi alih) perlu diterapkan ATP Program penting untuk dikembangkan agar menunjang keberhasilan pengobatan dengan antibiotika yang rasional